Findings
Limited evidence of clinical validity from pilot trials due to cost, time, and regulatory complexities.
Lack of standards for data integration across different tools and platforms.
Potential biases introduced by pre-existing algorithms.
Opaque data processing methods in BioMeTs.

Recommendations
Develop data, hardware, and software standards for BioMeTs.
Improve regulations for data rights, access, privacy, and governance.
Provide guidance on analytical methodologies for BioMeT data validation.

Regulatory Considerations
Early regulatory interactions with agencies like the FDA and EMA.
Ensuring data quality, integrity, reliability, and robustness.
Understanding regulatory pathways for BioMeTs in clinical trials.

Findings
DMOs offer a novel method to monitor mobility performance in real-world conditions across multiple diseases, but no current gold standard exists for direct comparison.
A 24-month observational clinical study with disease-specific cohorts is considered a valid exploratory step for validating DMOs.
Disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) are supported as anchors for evaluating DMOs’ predictive capacity and construct validity.
The Later-Life Function & Disability Instrument (LLFDI) requires additional validation for use as a disease-independent biomarker, especially in younger populations.
Validation of DMOs as surrogate endpoints is contingent upon demonstrating robust correlations with established clinical outcomes in each disease.

Recommendations
Continue using disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) to validate DMOs within individual diseases.
Validate the LLFDI tool across diverse age groups and diseases to establish its utility as a disease-independent biomarker.
Explore combining multiple DMOs to enhance predictive capacity where applicable.
Focus on disease-specific biomarkers until sufficient evidence supports the use of DMOs as disease-independent endpoints.
Conduct randomized clinical trials as a follow-up to the observational study to evaluate DMOs’ responsiveness to therapeutic interventions.

Regulatory Considerations
Established endpoints must be used to validate DMOs for consideration as secondary endpoints in regulatory submissions.
Disease-specific validation should be prioritized over disease-independent validation until robust evidence supports the latter.
Provide standardized and regionally consistent criteria for endpoints such as care home admission (PFF) or fall frequency (PD).
Correlate DMOs with widely accepted clinical measures (e.g., FEV1 in COPD) to strengthen regulatory positioning.
Incorporate randomization in future studies to further validate DMOs as surrogate endpoints predictive of clinical outcomes.

Findings
A universally applicable evidentiary standard for biomarker qualification is not feasible; the necessary level of evidence depends entirely on the specific Context of Use (COU). The framework emphasizes that the strength of evidence is evaluated based on the potential risk and benefit associated with the biomarker's intended application in drug development. The relationship between a biomarker and clinical outcomes must be robustly demonstrated, but there are no fixed quantitative criteria for this association. The overall confidence in a biomarker is derived from a combination of analytical validation, clinical validation, and the strength of the biological rationale.

Recommendations
Sponsors should clearly define the specific COU for the biomarker early in the development process, as this will dictate the required evidentiary support. It is recommended that sponsors engage with the FDA throughout the biomarker development and validation process to ensure alignment on the evidentiary requirements. Submissions for biomarker qualification should include a comprehensive package of evidence detailing the analytical validation (how well the test measures the biomarker) and the clinical validation (how well the biomarker relates to a clinical endpoint). Sponsors should provide a strong biological rationale for the biomarker's role in the disease process and its relevance to the proposed COU.

Regulatory Considerations
The FDA's evidentiary framework is designed to be a flexible, risk-based approach to biomarker qualification. The qualification is specific to the COU for which it was evaluated and does not imply acceptance for other uses. The framework is intended to support the use of biomarkers as Drug Development Tools (DDTs), which can include uses for patient selection, as surrogate endpoints, or to demonstrate a drug's mechanism of action. The level of regulatory scrutiny is proportional to the impact the biomarker will have on drug development and clinical decision-making. Qualified biomarkers can help to de-risk and streamline the drug development process.

Findings
Rapid development of digital biomarkers through sensors and personal devices.
Lack of established standards for evaluating digital biomarkers.
Challenges in handling large volumes of data, including missing data and outliers.

Recommendations
Improve the quality and reproducibility of research supporting biomarker use.
Ensure rigorous methodology in biomarker assessment.
Foster collaboration across disciplines for biomarker development.
Develop standards for linking digital phenotypes to traditional outcomes.
Address data handling challenges in digital health technologies.

Regulatory Considerations
Substantial validation work required for FDA approval of biomarkers.
Importance of rigorous scientific evidence for regulatory approval.
Need for collaboration in regulatory science to advance biomarker development.